Author:
Lv Hengliang,Zhang Xin,Zhang Xueli,Bai Junzhu,You Shumeng,Li Xuan,Li Shenlong,Wang Yong,Zhang Wenyi,Xu Yuanyong
Abstract
Abstract
Background
Tuberculosis(TB) remains a pressing public health challenge, with multidrug-resistant tuberculosis (MDR-TB) emerging as a major threat. And healthcare authorities require reliable epidemiological evidence as a crucial reference to address this issue effectively. The aim was to offer a comprehensive epidemiological assessment of the global prevalence and burden of MDR-TB from 1990 to 2019.
Methods
Estimates and 95% uncertainty intervals (UIs) for the age-standardized prevalence rate (ASPR), age-standardized incidence rate (ASIR), age-standardized disability-adjusted life years rate (ASR of DALYs), and age-standardized death rate (ASDR) of MDR-TB were obtained from the Global Burden of Disease (GBD) 2019 database. The prevalence and burden of MDR-TB in 2019 were illustrated in the population and regional distribution. Temporal trends were analyzed by using Joinpoint regression analysis to calculate the annual percentage change (APC), average annual percentage change (AAPC) and its 95% confidence interval(CI).
Results
The estimates of the number of cases were 687,839(95% UIs: 365,512 to 1223,262), the ASPR were 8.26 per 100,000 (95%UIs: 4.61 to 15.20), the ASR of DALYs were 52.38 per 100,000 (95%UIs: 22.64 to 97.60) and the ASDR were 1.36 per 100,000 (95%UIs: 0.54 to 2.59) of MDR-TB at global in 2019. Substantial burden was observed in Africa and Southeast Asia. Males exhibited higher ASPR, ASR of DALYs, and ASDR than females across most age groups, with the burden of MDR-TB increasing with age. Additionally, significant increases were observed globally in the ASIR (AAPC = 5.8; 95%CI: 5.4 to 6.1; P < 0.001), ASPR (AAPC = 5.9; 95%CI: 5.4 to 6.4; P < 0.001), ASR of DALYs (AAPC = 4.6; 95%CI: 4.2 to 5.0; P < 0.001) and ASDR (AAPC = 4.4; 95%CI: 4.0 to 4.8; P < 0.001) of MDR-TB from 1990 to 2019.
Conclusions
This study underscored the persistent threat of drug-resistant tuberculosis to public health. It is imperative that countries and organizations worldwide take immediate and concerted action to implement measures aimed at significantly reducing the burden of TB.
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Bagcchi S. WHO’s Global Tuberculosis Report 2022. Lancet Microbe. 2023;4:e20.
2. Margarit A, Simó S, Rozas L, Deyà-Martínez À, Barrabeig I, Gené A, et al. [Adolescent tuberculosis; a challenge and opportunity to prevent community transmission]. Pediatr (Barc). 2017;86:110–4.
3. Salari N, Kanjoori AH, Hosseinian-Far A, Hasheminezhad R, Mansouri K, Mohammadi M. Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis. Infect Dis Poverty. 2023;12:57.
4. Global tuberculosis report 2023. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization; 2023.
5. Global. tuberculosis report 2020. https://www.who.int/publications-detail-redirect/9789240013131. Accessed 7 Jun 2023.